The Latin American interventional oncology device market will see moderate growth, driven by an increasing patient population, adoption of premium-priced devices, and the introduction of new devices in the countries covered. However, cost constraints in the region's publicly funded health care systems will limit the pace of revenue expansion.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in Latin America across a 10-year period.
The ablation device market is dominated by RF ablation, however, new technologies are making their way in the market and will cannibalize the RF ablation device market in the forecast period
What are the advantages and disadvantages of each type of ablation device offered by competitors and how do these differences affect adoption for different indications?
What is the current status of device availability in the geographies covered?
Radioembolization spheres continue to represent the largest segment of the embolization particle market, although the microsphere and DEB markets will also experience growth over the forecast period.
How will outcomes of trials like SIRFLOX and FOXFIRE affect the adoption and usage of radioembolization spheres?
What factors are contributing to the growth of the Latin American microsphere and DEB markets?
The launch of new products will drive the growth of Latin American interventional oncology device market
What new products are anticipated to be launched in Latin America?
What product features are companies focusing on during novel product development?
- Interventional Oncology Devices - Market Insights - Latin America
Author(s): Bishwjit Ghoshal, MBA
Bishwjit Ghoshal is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in interventional oncology and vascular access device markets. Bishwjit holds a Bachelor's degree in Pharmacy from the University of Delhi and an MBA in Pharmaceutical Marketing from the National Institute of Pharmaceutical Education and Research, Mohali.
Follow Bishwjit on twitter: @Bishwjit_DRG